Cala Health Hopes To Jolt Essential Tremor Market With Wrist-Worn Non-Invasive Stimulation
Cala Health’s FDA-cleared Cala Trio wearable for treating essential tremor is currently being tested in Parkinson’s disease patients and is targeting a $20bn global market opportunity.
You may also be interested in...
In this roundup feature focusing on developments in digital health, Medtech Insight highlights interviews with Medtronic, Abbott and Congenica, partnerships and launches, and AI and cybersecurity announcements from November.
Cala Health expects to initiate telemedicine-based clinical trials of Cala Trio in patients with Parkinson’s disease by year-end.
Exec Chat: Medtronic’s Linnea Burman Targets 'Consensus-Driven Care' Using AI, Robotics In Spine Care
Linnea Burman, the general manager of enabling technologies for cranial and spinal technologies at Medtronic, talked to Medtech Insight about plans for the Mazor spinal robotic system, the incoming new president of the division, and other new developments.